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We thank Dr. Sperling and her colleagues from Merck &
Co. for their comments on our case reports of thrombosis
occurring in temporal proximity to institution of treatment with
the selective COX-2 inhibitor celecoxib. Case reports clearly
cannot establish a cause-and-effect relationship between these
events. However, we used these case reports to propose the
hypothesis that in certain individuals who are at increased risk for
thrombosis, inhibition of endothelial prostacyclin without concur-
rent inhibition of platelet thromboxane may alter the coagulation
balance toward thrombosis. We believe that this remains a viable
hypothesis until such time as it is specifically tested in valid animal
models and prospective clinical studies.
Several points made by Sperling et al deserve further
comment. They imply in their letter that because high-risk
patients are prone to thrombotic events, the hypothesis that
selective inhibition of COX-2 could be a contributing factor is
invalid. We believe that it is in precisely this high-risk patient
population that the first indications of a propensity for pro-
thrombotic risk associated with selective COX-2 inhibition will
be identified. Sperling and colleagues note that their market-
ing data indicate that patients with SLE are prescribed selec-
tive COX-2 inhibitors, and that a query of the Merck & Co.
database failed to identify patients with adverse events similar
to the ones we reported. It is not clear from their letter
whether there is a specific effort to prospectively evaluate
patients with SLE or other connective tissue diseases for
differences in the rate of thrombosis among those receiving
selective COX-2 inhibitors compared with those taking tradi-
tional NSAIDs, with stratification according to risk for throm-
bosis at entry into a study. If the database consists only of
voluntary adverse-events reporting by individual practitioners,
thus introducing the question of reporting bias, Sperling et al
are effectively suggesting an alternative hypothesis but have
not refuted the hypothesis generated by our report.
Selective COX-2 inhibitors are expected to have a
more substantial impact on the ratio of thromboxane to
prostacyclin because they inhibit endothelial prostacyclin pro-
duction without inhibiting platelet thromboxane production
(1–4). Sperling and coworkers state that there is no evidence
that the degree of prostacyclin synthesis inhibition achieved
with selective COX-2 inhibitors can overwhelm the ability of
endothelial-derived prostacyclin to prevent formation of a
platelet thrombus. There is also no evidence to the contrary.
The study cited in support of their argument examined the
recovery of endothelial cell prostacyclin production in vitro
after treatment with aspirin, an irreversible inhibitor of COX
(5). Since endothelial cells continually replenish COX, short-
term exposure to aspirin would not be expected to inhibit
prostacyclin effectively over time. In the in vivo setting, aspirin
has a very short half-life, further reducing the expected effects
on endothelial prostacyclin production. This is precisely why
aspirin is an excellent antithrombotic agent.
Selective COX-2 inhibitors have demonstrated effects on
systemic production of prostacyclin (2,3). This translates into loss
of coronary artery vasodilation in response to administration of
arachidonic acid in dogs treated with specific COX-2 inhibitors
(Hennan JK, Lucchesi B, University of Michigan: personal com-
munication), an observation that confirms the COX-2 depen-
dence of endogenous prostacyclin production in the vasculature.
Investigators are beginning to address the important role of
prostacyclin as an inhibitor of thrombosis, using genetic models
(6) and pharmacologic probes. Further studies must be com-
pleted in order to properly examine our hypothesis.
We agree with Sperling et al that specific COX-2
inhibitors are clearly not a substitute for aspirin in cardiovas-
cular prophylaxis. Neither, for that matter, are other NSAIDs.
We join them in urging physicians to assess patients individu-
ally for thrombotic risk and intervene as medically appropriate.
However, we maintain that appropriate vigilance is indicated
for patients with thrombotic risk factors who are treated with
selective COX-2 inhibitors.
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